Press Releases

Date	Title	PDF Version
Jan 31, 2011	Alexion Acquires Taligen Therapeutics and Creates Translational Medicine Group to Accelerate Development of Expanded Portfolio
Jan 27, 2011	Alexion Pharmaceuticals to Report Fourth Quarter and Full Year 2010 Results on Thursday, February 10, 2011
Jan 04, 2011	Alexion to Present at the 29th Annual JP Morgan Healthcare Conference
Dec 06, 2010	Long-Term Efficacy, Safety and Survival Outcomes of PNH Patients Treated with Soliris® (eculizumab) Reported at ASH Annual Meeting
Dec 06, 2010	Hemolysis Is Associated with Increased Mortality and Thrombosis in Patients with PNH
Dec 05, 2010	Alexion Reports Results from First Clinical Trial of Novel Anti-Cancer Antibody Samalizumab at ASH Annual Meeting
Nov 24, 2010	Alexion to Present at the Piper Jaffray 22nd Annual Health Care Conference
Nov 20, 2010	Phase 2 Study of Eculizumab (Soliris®) in Patients with aHUS Resistant to Plasma Therapy Met Primary and Secondary Endpoints with High Statistical and Clinical Significance
Nov 08, 2010	Researchers to Present New Long-Term Data on Soliris® (eculizumab) in Patients with PNH at the ASH Annual Meeting
Nov 04, 2010	Alexion to Present at the Credit Suisse 2010 Healthcare Conference

Search